Latest news with #CSPCPharmaceuticalGroup
Business Insider
2 days ago
- Business
- Business Insider
Analysts Conflicted on These Healthcare Names: CSPC Pharmaceutical Group (OtherCHJTF) and Moderna (MRNA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSPC Pharmaceutical Group (CHJTF – Research Report) and Moderna (MRNA – Research Report). Confident Investing Starts Here: CSPC Pharmaceutical Group (CHJTF) Jefferies analyst Chu Wang downgraded CSPC Pharmaceutical Group to Sell yesterday and set a price target of HK$5.00. The company's shares closed last Tuesday at $0.81. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSPC Pharmaceutical Group with a $0.84 average price target. Moderna (MRNA) In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on Moderna. The company's shares closed last Friday at $26.56. According to Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. Moderna has an analyst consensus of Hold, with a price target consensus of $49.36, implying an 87.4% upside from current levels. In a report issued on May 27, Barclays also maintained a Hold rating on the stock with a $40.00 price target.
Business Insider
4 days ago
- Business
- Business Insider
Citi Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
In a report released yesterday, from Citi maintained a Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report), with a price target of HK$9.20. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Citi, CSPC Pharmaceutical Group also received a Buy from Morgan Stanley's Yolanda Hu in a report issued yesterday. However, on the same day, Macquarie maintained a Hold rating on CSPC Pharmaceutical Group (Other OTC: CHJTF). The company has a one-year high of $0.96 and a one-year low of $0.44. Currently, CSPC Pharmaceutical Group has an average volume of 35.52K.
Business Insider
4 days ago
- Business
- Business Insider
Morgan Stanley Remains a Buy on CSPC Pharmaceutical Group (CHJTF)
Morgan Stanley analyst Yolanda Hu maintained a Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report) yesterday and set a price target of HK$6.80. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hu is ranked #9102 out of 9552 analysts. In addition to Morgan Stanley, CSPC Pharmaceutical Group also received a Buy from Nomura's Jialin Zhang in a report issued on May 29. However, yesterday, Macquarie maintained a Hold rating on CSPC Pharmaceutical Group (Other OTC: CHJTF).
Business Insider
4 days ago
- Business
- Business Insider
CSPC Pharmaceutical Group (CHJTF) Receives a Hold from Bernstein
In a report released on May 29, Rebecca Liang from Bernstein maintained a Hold rating on CSPC Pharmaceutical Group (CHJTF – Research Report), with a price target of HK$5.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Liang is a 3-star analyst with an average return of 14.1% and a 64.71% success rate. Liang covers the Healthcare sector, focusing on stocks such as Innovent Biologics, BeiGene, and Akeso, Inc.. In addition to Bernstein, CSPC Pharmaceutical Group also received a Hold from Macquarie's Tony Ren in a report issued yesterday. However, on May 29, Nomura maintained a Buy rating on CSPC Pharmaceutical Group (Other OTC: CHJTF).
South China Morning Post
20-05-2025
- Business
- South China Morning Post
Hong Kong stocks rise after China cuts borrowing costs for first time in 7 months
Hong Kong stocks rose on Tuesday after China cut key interest rates for the first time in seven months. The Hang Seng Index gained 0.9 per cent to 23,550.74 at 9.55am local time. The Hang Seng Tech Index also added 0.9 per cent. On the mainland, the CSI 300 Index climbed 0.2 per cent and the Shanghai Composite Index added 0.1 per cent. CSPC Pharmaceutical Group advanced 5.2 per cent to HK$6.27 and Sino Pharmaceutical gained 3.7 per cent to HK$4.21. Xiaomi climbed 3.2 per cent to HK$54 and Alibaba Group Holding rose 2.2 per cent to HK$121.80. The People's Bank of China on Tuesday lowered the one-year loan prime rate (LPR) to 3 per cent from 3.1 per cent, while the five-year rate, a reference for long-term loans including mortgages, was cut to 3.5 per cent from 3.6 per cent. The LPRs were last cut by 25 basis points in October following a broad easing by the central bank. Contemporary Amperex Technology , the biggest stock offering in Hong Kong this year, jumped 12 per cent to HK$294 on the first day of trading. The maker of lithium-ion batteries for electric vehicles surged by as much as 14 per cent at the opening bell. Elsewhere in Asia-Pacific, Japan's Nikkei 225 climbed 0.5 per cent, South Korea's Kospi rose 0.2 per cent and Australia's S&P/ASX 200 added 0.6 per cent.
